The privately-owned company, which specialises in drugs used in the treatment of lung disease and asthma, will be acquired in a deal worth up to $1.15 billion.
AstraZeneca, the UK's second largest drugs company, has been trying to gain a foothold in the emerging market for a new class of lung treatments known as LABA/LAMA drugs, administered via an inhaler. In purchasing Pearl Therapeutics it hopes to tap into a market where such drugs are used in the treatment of chronic obstructive pulmonary disease, which affects about 210 million people worldwide.